Basilea Pharmaceutica Ag Stock Buy Hold or Sell Recommendation
| BPMUF Stock | USD 52.83 0.00 0.00% |
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding Basilea Pharmaceutica AG is 'Hold'. Macroaxis provides Basilea Pharmaceutica buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BPMUF positions.
Check out Basilea Pharmaceutica Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Basilea and provide practical buy, sell, or hold advice based on investors' constraints. Basilea Pharmaceutica AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
Basilea |
Execute Basilea Pharmaceutica Buy or Sell Advice
The Basilea recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Basilea Pharmaceutica AG. Macroaxis does not own or have any residual interests in Basilea Pharmaceutica AG or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Basilea Pharmaceutica's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | OK | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Basilea Pharmaceutica Trading Alerts and Improvement Suggestions
| The company reported the revenue of 148.12 M. Net Loss for the year was (6.83 M) with profit before overhead, payroll, taxes, and interest of 30.89 M. | |
| Basilea Pharmaceutica AG has accumulated about 140.74 M in cash with (32.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.89. |
Basilea Pharmaceutica Returns Distribution Density
The distribution of Basilea Pharmaceutica's historical returns is an attempt to chart the uncertainty of Basilea Pharmaceutica's future price movements. The chart of the probability distribution of Basilea Pharmaceutica daily returns describes the distribution of returns around its average expected value. We use Basilea Pharmaceutica AG price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Basilea Pharmaceutica returns is essential to provide solid investment advice for Basilea Pharmaceutica.
| Mean Return | 0.05 | Value At Risk | 0.00 | Potential Upside | 0.00 | Standard Deviation | 0.38 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Basilea Pharmaceutica historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Basilea Pharmaceutica Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Basilea Pharmaceutica or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Basilea Pharmaceutica's price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Basilea pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.03 | |
β | Beta against Dow Jones | 0.03 | |
σ | Overall volatility | 0.39 | |
Ir | Information ratio | -0.24 |
Basilea Pharmaceutica Volatility Alert
Basilea Pharmaceutica AG exhibits very low volatility with skewness of 8.12 and kurtosis of 66.0. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Basilea Pharmaceutica's pink sheet risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Basilea Pharmaceutica's pink sheet price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Basilea Pharmaceutica Fundamentals Vs Peers
Comparing Basilea Pharmaceutica's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Basilea Pharmaceutica's direct or indirect competition across all of the common fundamentals between Basilea Pharmaceutica and the related equities. This way, we can detect undervalued stocks with similar characteristics as Basilea Pharmaceutica or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Basilea Pharmaceutica's fundamental indicators could also be used in its relative valuation, which is a method of valuing Basilea Pharmaceutica by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Basilea Pharmaceutica to competition |
| Fundamentals | Basilea Pharmaceutica | Peer Average |
| Return On Asset | 0.0261 | -0.14 |
| Profit Margin | 0.01 % | (1.27) % |
| Operating Margin | 0.06 % | (5.51) % |
| Current Valuation | 724.26 M | 16.62 B |
| Shares Outstanding | 11.93 M | 571.82 M |
| Shares Owned By Insiders | 3.07 % | 10.09 % |
| Shares Owned By Institutions | 29.13 % | 39.21 % |
| Price To Earning | 200.00 X | 28.72 X |
| Price To Sales | 4.09 X | 11.42 X |
| Revenue | 148.12 M | 9.43 B |
| Gross Profit | 30.89 M | 27.38 B |
| EBITDA | 2.11 M | 3.9 B |
| Net Income | (6.83 M) | 570.98 M |
| Cash And Equivalents | 140.74 M | 2.7 B |
| Cash Per Share | 11.89 X | 5.01 X |
| Total Debt | 94.54 M | 5.32 B |
| Current Ratio | 1.36 X | 2.16 X |
| Book Value Per Share | (5.67) X | 1.93 K |
| Cash Flow From Operations | (32.02 M) | 971.22 M |
| Earnings Per Share | 0.25 X | 3.12 X |
| Number Of Employees | 177 | 18.84 K |
| Beta | 0.88 | -0.15 |
| Market Capitalization | 626.06 M | 19.03 B |
| Total Asset | 247.27 M | 29.47 B |
| Retained Earnings | (908 M) | 9.33 B |
| Working Capital | 219 M | 1.48 B |
| Current Asset | 283 M | 9.34 B |
| Current Liabilities | 64 M | 7.9 B |
| Z Score | -0.6 | 8.72 |
| Net Asset | 247.27 M |
Basilea Pharmaceutica Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Basilea . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Basilea Pharmaceutica Buy or Sell Advice
When is the right time to buy or sell Basilea Pharmaceutica AG? Buying financial instruments such as Basilea Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Basilea Pharmaceutica in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Utilities - Regulated Electric Thematic Idea Now
Utilities - Regulated Electric
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Utilities - Regulated Electric theme has 7 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Utilities - Regulated Electric Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Basilea Pink Sheet
Basilea Pharmaceutica financial ratios help investors to determine whether Basilea Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Basilea with respect to the benefits of owning Basilea Pharmaceutica security.